Micafungina Hikma

Micafungin, the active ingredient in Micafungina Hikma, is an echinocandin presented as an injectable formulation for intravenous use. It is indicated for the treatment of invasive candidiasis, esophageal candidiasis, and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungina Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and research institutions worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for injectable products globally.

Micafungin is an echinocandin antifungal used to treat serious Candida infections and to prevent infection in high‑risk transplant patients.

- Invasive candidiasis: effective treatment that clears bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: alleviates mucosal infection and promotes healing of esophageal lesions. - Prophylaxis in hematopoietic stem cell transplant recipients: reduces the incidence of invasive Candida infections during the neutropenic phase.

Micafungin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing pain. - Elevated liver enzymes: mild increase in ALT/AST. - Phlebitis at infusion site: irritation or redness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury with jaundice. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Renal impairment: acute kidney injury. - Hematologic abnormalities: neutropenia or thrombocytopenia.

When using Micafungin, clinicians should observe several precautionary measures to ensure patient safety. - Assess liver function: monitor ALT, AST, bilirubin before and during therapy. - Evaluate renal function: adjust use in patients with pre‑existing kidney disease. - Monitor for hypersensitivity: discontinue if signs of severe allergic reaction appear. - Use caution in neonates and pediatric patients: limited safety data available. - Avoid concomitant use with strong CYP3A4 inducers: may reduce exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Rifampin: strong inducer of hepatic enzymes that markedly reduces micafungin plasma levels. - Cyclosporine: may increase micafungin exposure, raising risk of liver toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole, voriconazole): may alter micafungin metabolism, requiring monitoring. - Immunosuppressants (e.g., tacrolimus): potential additive hepatotoxicity. - Warfarin: possible effect on anticoagulation parameters; monitor INR. - Concomitant nephrotoxic agents: increased risk of renal impairment.